Orbimed Advisors - TRILLIUM THERAPEUTICS INC ownership

TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 130 filers reported holding TRILLIUM THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.

Quarter-by-quarter ownership
Orbimed Advisors ownership history of TRILLIUM THERAPEUTICS INC
ValueSharesWeighting
Q2 2021$32,226,000
-5.3%
3,322,300
+4.9%
0.33%
+2.5%
Q1 2021$34,012,000
-21.9%
3,166,900
+7.0%
0.32%
-16.5%
Q4 2020$43,545,000
+144.6%
2,960,200
+136.3%
0.38%
+70.1%
Q3 2020$17,799,000
+81.7%
1,252,600
+3.4%
0.22%
+62.3%
Q2 2020$9,797,000
+202.8%
1,211,000
+51.2%
0.14%
+155.6%
Q1 2020$3,236,000801,0000.05%
Other shareholders
TRILLIUM THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Anson Funds Management LP 174,174$298,0000.17%
Matrix Capital Management Company, LP 2,288,560$3,913,0000.13%
Samsara BioCapital, LLC 71,619$122,0000.12%
NEA Management Company, LLC 1,250,000$2,138,0000.08%
Tekla Capital Management LLC 446,099$763,0000.03%
PLATINUM INVESTMENT MANAGEMENT LTD 175,339$306,0000.01%
Artal Group S.A. 150,000$257,0000.01%
Baker Brothers Advisors 505,262$864,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 20,044$34,0000.01%
OXFORD ASSET MANAGEMENT LLP 57,055$98,0000.00%
View complete list of TRILLIUM THERAPEUTICS INC shareholders